Insulin Detemir

China [CN]

Dete insulin is another new type of soluble long-acting human insulin analogue following insulin glargine. Developed by NovoNordisk, it was launched in Europe in 2004 and approved for the treatment of type 2 diabetes. Dete insulin modifies the structure of human insulin by removing threonine at position 30 of the B chain and attaching 14-carbon fatty acids to lysine at position 29 of the B chain. The changes in two structures make it easier for the deter insulin monomer to self-form a hexmer. Additionally, the connection of myoglobin acid to lysine at position 29 of the B chain enhances its ability to bind to albumin, enabling it to have a slow release effect after entering the body without affecting its hypoglycemic effect. Dete insulin has good solubility. It becomes neutral after dissolution and remains in a solution state after injection administration. Dete insulin preparations are colorless, clear and neutral solutions. Even after subcutaneous injection, they remain in a solution state, with slow absorption and diffusion. The main mechanism of their prolongs effect is as follows: ① Insulin molecules exist in a unique hexamer form, thereby delaying the rate of absorption and diffusion. After entering the peripheral blood circulation, 98% of Dete insulin reversibly binds to albumin, further delaying the distribution and diffusion speed of insulin to organs and tissues, prolonging the duration of action, and thus achieving a more sustained, stable and good blood sugar control effect. It takes effect 1.5 hours after subcutaneous injection, with an effective duration of about 24 hours. The plasma concentration is stable without a peak, and the peak-valley fluctuation is small. It is generally used in combination with short-acting insulin or oral hypoglycemic drugs. Its main function is to regulate glucose metabolism by binding to insulin receptors, promote the uptake of glucose by skeletal muscle cells, reduce the production of glucose in the liver, and also inhibit the decomposition of fat and protein and promote protein synthesis. This product can not only rapidly lower blood sugar, but also reduce the risk of hypoglycemia, especially nocturnal hypoglycemia